{"id":3733,"date":"2025-05-19T12:00:33","date_gmt":"2025-05-19T10:00:33","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=3733"},"modified":"2025-05-19T09:54:40","modified_gmt":"2025-05-19T07:54:40","slug":"afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/","title":{"rendered":"Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma"},"content":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=”In a new phase 2 trial afami-cel showed durable responses in heavily pretreated patients, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy” font_container=”tag:h3|text_align:left” use_theme_fonts=”yes”][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_column_text]A new phase 2 trial recently published on The Lancet<\/a>\u00a0shows that afamitresgene autoleucel (afami-cel) can induce durable responses with an acceptable benefit-to-risk profile in heavily pretreated HLA-eligible patients with MAGE-A4-expressing advanced synovial sarcoma.<\/p>\n

T-cell receptor therapies have led to important advances in the treatment of certain subsets of B-cell leukaemia and lymphoma, but none has been approved for the treatment of any solid tumor. Affinity-optimised engineered T-cell receptors have emerged as a promising tool for application of autologous T cells to treat solid tumors. MAGE-A4, a cancer testis antigen, is expressed in germline tissue and various solid tumors, including synovial sarcoma and myxoid round cell liposarcoma, and is a promising target for cancer immunotherapy. Afami-cel is an autologous T-cell receptor T-cell therapy engineered to express an affinity-enhanced T-cell receptor specifically targeting a MAGE-A4 antigen; in a phase 1 trial afami-cel has been evaluated in patients with relapsing or refractory solid tumors expressing MAGE-4, ranging from synovial sarcoma to head and neck cancers.\u00a0 An acceptable benefit-to-risk profile and durable responses were observed especially in patients with synovial sarcoma, therefore this phase 2 trial involved 52 heavily pretreated patients followed-up for a median of 32.6 months. Overall response rate was 37% overall, 39% for patients with synovial sarcoma, and 25% for patients with myxoid round cell liposarcoma, with cytopenias as the most common grade 3 or worse adverse events. As authors conclude, \u00abThis study shows the ability to effectively target solid tumor cancer antigens with T-cell receptor therapy and highlights MAGE-A4 as a new immunotherapy target for treatment of synovial sarcoma\u00bb.[\/vc_column_text][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”3744″ img_size=”large”][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=”In a new phase 2 trial afami-cel showed durable responses in heavily pretreated patients, providing a rationale for the treatment of solid tumors with a [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":3745,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-3733","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"\nAfamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"In a new phase 2 trial afami-cel showed durable responses in heavily pretreated patients, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"In a new phase 2 trial afami-cel showed durable responses in heavily pretreated patients, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-19T10:00:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2025\/05\/Image_Lancet_19May25-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1599\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma\",\"datePublished\":\"2025-05-19T10:00:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/\"},\"wordCount\":340,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Image_Lancet_19May25-scaled.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/\",\"name\":\"Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Image_Lancet_19May25-scaled.jpg\",\"datePublished\":\"2025-05-19T10:00:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"In a new phase 2 trial afami-cel showed durable responses in heavily pretreated patients, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Image_Lancet_19May25-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Image_Lancet_19May25-scaled.jpg\",\"width\":2560,\"height\":1599},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma - Fondazione Gianni Bonadonna","description":"In a new phase 2 trial afami-cel showed durable responses in heavily pretreated patients, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/","og_locale":"en_US","og_type":"article","og_title":"Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma - Fondazione Gianni Bonadonna","og_description":"In a new phase 2 trial afami-cel showed durable responses in heavily pretreated patients, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2025-05-19T10:00:33+00:00","og_image":[{"width":2560,"height":1599,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2025\/05\/Image_Lancet_19May25-scaled.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma","datePublished":"2025-05-19T10:00:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/"},"wordCount":340,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2025\/05\/Image_Lancet_19May25-scaled.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/","name":"Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2025\/05\/Image_Lancet_19May25-scaled.jpg","datePublished":"2025-05-19T10:00:33+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"In a new phase 2 trial afami-cel showed durable responses in heavily pretreated patients, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2025\/05\/Image_Lancet_19May25-scaled.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2025\/05\/Image_Lancet_19May25-scaled.jpg","width":2560,"height":1599},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/afamitresgene-autoleucel-in-advanced-synovial-sarcoma-and-myxoid-round-cell-liposarcoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=3733"}],"version-history":[{"count":2,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3733\/revisions"}],"predecessor-version":[{"id":3749,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3733\/revisions\/3749"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/3745"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=3733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=3733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=3733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}